Intero Biosystems Inc.

Intero Biosystems Inc., based in Aurora, Colorado, is a for-profit biotech company that develops stem cell-derived human intestinal organoid platforms for preclinical drug discovery and toxicity testing. The vendor operates exclusively as a prime recipient of federal research grants from the National Institutes of Health, with no contract prime work or subcontractor history in the current footprint.

Intero Biosystems' federal customer base is singular and concentrated: all three recent awards come from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, the Small Business Innovation Research program. The vendor received a $349,952 Phase I SBIR project grant awarded June 20, 2025, with ultimate completion June 19, 2026, to develop and validate a stem cell-derived human intestinal organoid screening platform in collaboration with the University of Michigan. That work focused on optimization and validation of the HIO system for cytotoxicity and cell viability assays commonly used in preclinical drug screening, plus development of an intestinal fibrosis disease model for drug efficacy testing. The vendor then moved into Phase II, receiving a $1.046897 million project grant on July 1, 2026, running through June 30, 2028, to scale production methods and validate assay readouts for high-throughput screening, establishing standardized quality control, shelf-life, and cryopreservation benchmarks. In July 2026, Intero Biosystems received a second Phase I award of $349,824 for development of a human peristaltic intestinal organoid platform for drug discovery in gastrointestinal motility disorders, with performance in Ann Arbor, Michigan and completion July 14, 2027. The combined obligated dollars across all awards total $1.7 million.

Activity shows two awards in 2026 following one in 2025. Two of the three awards face ultimate completion within the next twenty-four months, positioning the vendor for potential Phase II or continued program recompete and expansion within the SBIR ecosystem. The vendor's capability set centers on microphysiological systems, organ-on-chip engineering, and translational research tools that model human intestinal biology to reduce drug candidate failure rates in preclinical stages.